Stilbene derivatives for adp-ribosyl cyclase inhibitors

Abstract

The present disclosure relates to bisphenyl compounds that are useful for inhibit the ADP-ribosyl cyclase (ADPR-cyclase). More particularly, the disclosed compounds can be used for treatment and prevention of hypertension, hypertensive cardiac hypertrophy, diabetes, and diabetic nephropathy, in which pathogenesis ADPR-cyclase is involved. The compounds and compositions of the invention can be used for treatment and prevention of cardiovascular disease and related disease states, particularly, hypertension or diabetes related disorders, such as, hypertensive cardiac hypertrophy, diabetic nephropathy, and the like.

1 . A bisphenyl compounds for inhibiting ADPR-cyclase in mammal. 
   
   
       2 . A compound of Formula I: 
     
       
         
         
             
             
         
       
       wherein: 
       X and Y are selected from C and N; 
       R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are each independently selected from hydrogen and hydroxyl; 
       X—Y is selected from a single bond or double bond. 
     
   
   
       3 . The compound of Formula I, wherein 4,4′-dihydroxyazobenzene as kidney specific ADPR-cyclase inhibitor. 
   
   
       4 . The compound of  claim 3 , wherein the therapeutically effective concentration ranges from about 0.0005 mM to about 50 mM. 
   
   
       5 . The compound of Formula I, wherein 2,2′-dihydroxyazobenzene as heart specific ADPR-cyclase inhibitor. 
   
   
       6 . The compound of  claim 5 , wherein the therapeutically effective concentration ranges from about 0.05 mM to about 100 mM. 
   
   
       7 . The compound of Formula I, wherein resveratrol as kidney ADPR-cyclase inhibitor. 
   
   
       8 . The compound of  claim 7 , wherein the therapeutically effective concentration ranges from about 0.01 mM to about 100 mM. 
   
   
       9 . The compound of Formula I, further comprising treating or preventing a cardiovascular or renal disease.